Increased number of shares and votes in Medivir

The number of shares and the number of votes in Medivir have changed as a result of exercise of employee stock options.

Today, the last trading day of the month, there are in total 28,593,555 shares, divided into 660,000 class A shares and 27,933,555 class B shares, and 34,533,555 votes in Medivir.

The above information has been made public in accordance with the Financial Instruments Trading Act. The information was submitted for publication at 07.00 am (CET) on 31 March 2011.

For more information about Medivir, please contact:
Rein Piir, CFO & VP Investor Relations, Mobile: +46 708 537 292

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is TMC435, a protease inhibitor which has recently entered phase 3 clinical development for hepatitis C and is partnered with Tibotec Pharmaceuticals. 

Medivir is also marketing its first product, the unique cold sore product Xerese™/Xerclear® which has recently been launched on the US market. Xerese™/Xerclear®, which has been approved in both the US and Europe. is partnered with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia and with Meda AB in North America, Canada and Mexico. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company’s website: www.medivir.se